Perjeta (pertuzumab) is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.
|10/08/2015||01/09/2015||Full Pharmacoeconomic Evaluation Recommended|
|17/11/2015||10/05/2016||Reimbursement Not Recommended|
Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.